We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Smear Test Detects Aggressive Ovarian Cancer Years before Clinical Diagnosis

By LabMedica International staff writers
Posted on 08 Dec 2023
Print article
Image: Cervical cell swabs offer the potential for population-wide screening for ovarian cancer (Photo courtesy of 123RF)
Image: Cervical cell swabs offer the potential for population-wide screening for ovarian cancer (Photo courtesy of 123RF)

Ovarian cancer, recognized as the deadliest gynecologic cancer, is particularly challenging due to its aggressive nature and poor prognosis. High-grade serous ovarian cancer (HGSOC) is the most common and deadly subtype. Tragically, over 70% of women diagnosed with HGSOC succumb to the disease within five years of their diagnosis. This high mortality rate is largely due to late detection, as the disease often lacks specific symptoms in its early stages. The survival rate for early-stage HGSOC (stage I) exceeds 90%, but drops to about 30% for those with advanced stages of the disease (stage III) and is even lower for stage IV, where distant metastases are present. The vast difference in survival rates between early and late stages underscores the critical importance of early detection in improving outcomes for HGSOC. However, efforts to develop effective early detection tests have historically been met with disappointment and skepticism. Now, a breakthrough has been achieved with a new test that assesses genomic instability from routine cervical smears, potentially identifying aggressive ovarian cancer up to nine years before clinical diagnosis.

This advancement was made possible by researchers at Humanitas University (Milan, Italy) who explored the possibility of using archival Papanicolaou (PAP) test smears which are commonly collected for cervical cancer screening, as a resource for early ovarian cancer detection. By conducting whole-genome sequencing on DNA from these PAP smears, they identified women who later developed HGSOC, characterized by a higher count of somatic copy number alterations (SCNAs) compared to those who remained cancer-free. This finding led to the development of the EVA (Early oVArian cancer) test, specifically designed for early HGSOC detection

In their retrospective study, the team analyzed PAP test smears collected during routine screenings, ranging from a month to 13.5 years before HGSOC diagnosis. The study included 113 women who were later diagnosed with HGSOC and 77 healthy controls. They assessed genome instability through shallow whole-genome sequencing of DNA from the PAP test samples, focusing on copy number profile abnormality (CPA). The results revealed significantly higher CPA levels in DNA from women who developed HGSOC compared to the healthy group. Integrating CPA scores into the EVA test yielded a sensitivity of 75%, a specificity of 96%, and an overall accuracy of 81%. Remarkably, the EVA test could detect HGSOC up to nine years before its clinical diagnosis.

“This finding confirms the continual shedding of tumor cells from fimbriae toward the endocervical canal, suggesting a new path for the early diagnosis of HGSOC,” noted the researchers.

Related Links:
Humanitas University

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.